Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003 ...Middle East

PR Newswire - News
Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia (the "phase I study"). The clinical data...

Hence then, the article about harbour biomed announces phase i study positive results on next generation anti ctla 4 antibody hbm4003 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003 )

Apple Storegoogle play

Last updated :

Also on site :